CL2013001433A1 - Composicion que comprende al menos una n-acetil lactosamina, al menos un oligosacarido sialilado al menos un oligosacarido fucosilado; y su uso en la prevencion de infecciones respiratorias agudas y/o para aliviar los sintomas de dichas infecciones. - Google Patents
Composicion que comprende al menos una n-acetil lactosamina, al menos un oligosacarido sialilado al menos un oligosacarido fucosilado; y su uso en la prevencion de infecciones respiratorias agudas y/o para aliviar los sintomas de dichas infecciones.Info
- Publication number
- CL2013001433A1 CL2013001433A1 CL2013001433A CL2013001433A CL2013001433A1 CL 2013001433 A1 CL2013001433 A1 CL 2013001433A1 CL 2013001433 A CL2013001433 A CL 2013001433A CL 2013001433 A CL2013001433 A CL 2013001433A CL 2013001433 A1 CL2013001433 A1 CL 2013001433A1
- Authority
- CL
- Chile
- Prior art keywords
- infections
- oligosaccharide
- relieve
- symptoms
- prevention
- Prior art date
Links
- 229920001542 oligosaccharide Polymers 0.000 title 2
- 150000002482 oligosaccharides Chemical class 0.000 title 2
- KFEUJDWYNGMDBV-UHFFFAOYSA-N (N-Acetyl)-glucosamin-4-beta-galaktosid Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 KFEUJDWYNGMDBV-UHFFFAOYSA-N 0.000 title 1
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 title 1
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 title 1
- 206010057190 Respiratory tract infections Diseases 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Pediatric Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10192230A EP2465509A1 (en) | 2010-11-23 | 2010-11-23 | Oligosaccharide composition for treating acute respiratory tract infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013001433A1 true CL2013001433A1 (es) | 2013-12-13 |
Family
ID=43728675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013001433A CL2013001433A1 (es) | 2010-11-23 | 2013-05-17 | Composicion que comprende al menos una n-acetil lactosamina, al menos un oligosacarido sialilado al menos un oligosacarido fucosilado; y su uso en la prevencion de infecciones respiratorias agudas y/o para aliviar los sintomas de dichas infecciones. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9763465B2 (es) |
| EP (2) | EP2465509A1 (es) |
| CN (1) | CN103582485A (es) |
| AU (1) | AU2011340882B2 (es) |
| BR (1) | BR112013012598A2 (es) |
| CA (1) | CA2818012A1 (es) |
| CL (1) | CL2013001433A1 (es) |
| IL (1) | IL226348A0 (es) |
| MX (1) | MX343321B (es) |
| PH (1) | PH12013500952B1 (es) |
| RU (1) | RU2593321C2 (es) |
| SG (1) | SG190323A1 (es) |
| TW (1) | TW201302205A (es) |
| WO (1) | WO2012076323A1 (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2719404T5 (es) | 2010-12-31 | 2024-09-18 | Abbott Lab | Composiciones nutricionales que comprenden oligosacáridos de leche humana para el uso en el tratamiento y/o prevención de la infección por rotavirus entérico |
| MY171620A (en) * | 2010-12-31 | 2019-10-21 | Abbott Lab | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers or children using human milk oligosaccharides |
| NZ612455A (en) | 2010-12-31 | 2015-02-27 | Abbott Lab | Human milk oligosaccharides to promote growth of beneficial bacteria |
| ES2708924T3 (es) | 2010-12-31 | 2019-04-12 | Abbott Lab | Procedimientos de uso de oligosacáridos de la leche humana para mejorar la salud respiratoria de las vías respiratorias |
| MX375120B (es) | 2010-12-31 | 2025-03-06 | Abbott Lab | Oligosacáridos de leche humana para modular la inflamación. |
| SG191799A1 (en) | 2010-12-31 | 2013-08-30 | Abbott Lab | Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof |
| EP2658549B1 (en) | 2010-12-31 | 2020-06-03 | Abbott Laboratories | Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents |
| BR112014001472A2 (pt) | 2011-07-22 | 2017-02-21 | Abbott Lab | galactooligossacarídeos para prevenir lesões e / ou promover a cicatrização do trato gastrointestinal |
| HK1199607A1 (en) | 2011-08-29 | 2015-07-10 | Abbott Laboratories | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| EP2745705A1 (en) * | 2012-12-18 | 2014-06-25 | Abbott Laboratories | Nutritional use of human milk oligosaccharides |
| US20150050245A1 (en) * | 2013-08-14 | 2015-02-19 | Tntgamble, Inc. | Methods and delivery system for beneficial additive and subtractive biological agents to promote balanced mammalian gastrointestinal flora |
| CN105682664A (zh) * | 2013-11-15 | 2016-06-15 | 雀巢产品技术援助有限公司 | 利用岩藻糖基化低聚糖预防或治疗非分泌型母亲诞下或喂养的婴儿的变态反应的组合物,尤其适用于有风险的婴儿或剖腹产婴儿 |
| EP3111942B1 (en) | 2013-11-15 | 2021-01-06 | Société des Produits Nestlé S.A. | Compositions for use in the prevention or treatment of urt infections in infants or young children at risk |
| EP3209308B1 (en) | 2014-10-24 | 2022-08-03 | Evolve Biosystems Inc. | Activated bifidobacteria and methods of use thereof |
| RU2720933C2 (ru) | 2014-10-31 | 2020-05-14 | Сосьете Де Продюи Нестле С.А. | Композиция, содержащая fut2-зависимые олигосахариды и лакто-n-неотетраозу, для применения с целью активации развития головного мозга и познавательной способности |
| US10987368B2 (en) | 2014-12-08 | 2021-04-27 | Glycom A/S | Synthetic composition for preventing or treating CVD |
| EP3229812A4 (en) * | 2014-12-08 | 2018-10-03 | Glycom A/S | Synthetic composition for treating metabolic disorders |
| US10881674B2 (en) | 2014-12-08 | 2021-01-05 | Glycom A/S | Synthetic composition for treating metabolic disorders |
| US10835544B2 (en) | 2014-12-08 | 2020-11-17 | Glycom A/S | Synthetic composition for regulating satiety |
| PH12017550041B1 (en) * | 2015-03-05 | 2022-08-05 | SociaTa Des Produits Nestla S A | Compositions for use in improving stool consistency or frequency in infants or young children |
| EP3264920B1 (en) * | 2015-03-05 | 2020-12-16 | Société des Produits Nestlé S.A. | Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children |
| ES2960750T3 (es) * | 2015-03-05 | 2024-03-06 | Glycom As | Oligosacáridos de la leche humana para el tratamiento de infecciones agudas del aparato respiratorio |
| WO2017021413A1 (en) * | 2015-08-04 | 2017-02-09 | Südzucker AG | Prophylactic use of inulin against sinusitis |
| EP3389404B1 (en) | 2015-12-15 | 2019-10-02 | Société des Produits Nestlé S.A. | Mixture of hmos |
| CN105725216A (zh) * | 2016-03-15 | 2016-07-06 | 天津普生源科技发展有限公司 | 一种含有gaba的助眠功能食品及其制备方法 |
| WO2018020473A1 (en) | 2016-07-28 | 2018-02-01 | Fonterra Co-Operative Group Limited | Dairy product and process |
| EP4477262A3 (en) * | 2016-09-07 | 2025-04-23 | Société des Produits Nestlé S.A. | Nutritional compositions for infants and/or young children |
| PH12019550208B1 (en) | 2017-05-24 | 2024-05-24 | SociaTa Des Produits Nestla S A | Hmos blends for use in infants or young children for health purposes |
| CN109043542A (zh) * | 2018-09-11 | 2018-12-21 | 内蒙古伊利实业集团股份有限公司 | 人乳寡糖和/或其前体在制备预防儿童龋齿疾病的组合物中的应用 |
| EP3920723A1 (en) * | 2019-02-04 | 2021-12-15 | N.V. Nutricia | Fermented formula with non digestible oligosaccharides for sleep improvement |
| KR20220005482A (ko) * | 2019-04-09 | 2022-01-13 | 인트린식 메디슨, 아이엔씨. | 통증 치료를 위한 면역조절 올리고당 |
| JP7516053B2 (ja) * | 2020-01-20 | 2024-07-16 | 森永乳業株式会社 | 組成物並びに飲食品組成物、栄養組成物および調製乳 |
| US11331329B2 (en) * | 2020-05-13 | 2022-05-17 | Glycosyn LLC | Fucosylated oligosaccharides for prevention of coronavirus infection |
| WO2021235486A1 (ja) * | 2020-05-22 | 2021-11-25 | 森永乳業株式会社 | 腸管発達促進用組成物、肺機能改善用組成物および免疫機能向上用組成物 |
| WO2022226311A1 (en) * | 2021-04-23 | 2022-10-27 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and a designed lipid component for improving lung function |
| CN118475253A (zh) * | 2021-12-20 | 2024-08-09 | 雀巢产品有限公司 | 分泌型IgA-生物制剂复合物及其用途 |
| JP7747590B2 (ja) * | 2022-06-29 | 2025-10-01 | 雪印メグミルク株式会社 | 気管支炎を予防するための栄養組成物 |
| CN117223859B (zh) * | 2023-10-11 | 2025-10-28 | 黑龙江飞鹤乳业有限公司 | 功能性组合物及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991016449A1 (en) | 1990-04-16 | 1991-10-31 | The Trustees Of The University Of Pennsylvania | Saccharide compositions, methods and apparatus for their synthesis |
| US5545553A (en) | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
| US6045854A (en) * | 1997-03-31 | 2000-04-04 | Abbott Laboraties | Nutritional formulations containing oligosaccharides |
| EP1062873A1 (en) * | 1999-12-13 | 2000-12-27 | N.V. Nutricia | Improved infant formula, protein hydrolysate for use in such an infant formula, and method for producing such a hydrolysate |
| US6630452B2 (en) * | 2000-02-17 | 2003-10-07 | Wyeth | Nutritional formulation containing prebiotic substances |
| DE60336480D1 (de) * | 2003-11-19 | 2011-05-05 | Nestec Sa | Isolierte Bakteriophage und ihre Verwendung in Lebensmitteln oder zur Sanierung der Fabrik-Umgebung |
| JP5236189B2 (ja) * | 2003-12-05 | 2013-07-17 | チルドレンズ ホスピタル メディカル センター | オリゴ糖組成物および感染症の治療における該組成物の使用 |
| DK1629850T4 (da) * | 2004-08-24 | 2013-07-01 | Nutricia Nv | Næringssammensætning indeholdende ufordøjelige oligosaccharider |
| WO2007144334A1 (en) * | 2006-06-13 | 2007-12-21 | Nestec S.A. | Prevention and treatment of otitis media with non-pathogenic bacterial strains |
| EP2044851A1 (en) | 2007-09-26 | 2009-04-08 | Nestec S.A. | Prevention of allergy at weaning |
| WO2009060073A1 (en) * | 2007-11-08 | 2009-05-14 | Nestec S.A. | Use of oligosaccharides containing n-acetyllactosamine for maturation of immune responses in neonates |
| EP2060257A1 (en) * | 2007-11-08 | 2009-05-20 | Nestec S.A. | Prevention and treatment of secondary infections following viral infection |
| EP2072052A1 (en) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
| EP2453901B1 (en) * | 2009-07-15 | 2014-09-10 | N.V. Nutricia | Fucosyllactose as breast milk identical non-digestible oligosaccharide for treating and/or preventing viral infections |
| EP2465508A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases |
| EP2465507A1 (en) | 2010-11-23 | 2012-06-20 | Nestec S.A. | Oligosaccharide composition for treating skin diseases |
| EP2454948A1 (en) * | 2010-11-23 | 2012-05-23 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
-
2010
- 2010-11-23 EP EP10192230A patent/EP2465509A1/en not_active Withdrawn
-
2011
- 2011-11-21 AU AU2011340882A patent/AU2011340882B2/en active Active
- 2011-11-21 MX MX2013005727A patent/MX343321B/es active IP Right Grant
- 2011-11-21 SG SG2013038179A patent/SG190323A1/en unknown
- 2011-11-21 BR BR112013012598A patent/BR112013012598A2/pt not_active IP Right Cessation
- 2011-11-21 WO PCT/EP2011/070563 patent/WO2012076323A1/en not_active Ceased
- 2011-11-21 EP EP11784695.6A patent/EP2643006A1/en not_active Withdrawn
- 2011-11-21 RU RU2013128570/15A patent/RU2593321C2/ru active
- 2011-11-21 CA CA2818012A patent/CA2818012A1/en not_active Abandoned
- 2011-11-21 CN CN201180056475.7A patent/CN103582485A/zh active Pending
- 2011-11-21 US US13/988,975 patent/US9763465B2/en active Active
- 2011-11-21 PH PH1/2013/500952A patent/PH12013500952B1/en unknown
- 2011-11-23 TW TW100142957A patent/TW201302205A/zh unknown
-
2013
- 2013-05-13 IL IL226348A patent/IL226348A0/en unknown
- 2013-05-17 CL CL2013001433A patent/CL2013001433A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2818012A1 (en) | 2012-06-14 |
| CN103582485A (zh) | 2014-02-12 |
| PH12013500952B1 (en) | 2018-12-12 |
| BR112013012598A2 (pt) | 2016-08-09 |
| TW201302205A (zh) | 2013-01-16 |
| IL226348A0 (en) | 2013-07-31 |
| MX343321B (es) | 2016-11-01 |
| RU2013128570A (ru) | 2014-12-27 |
| EP2643006A1 (en) | 2013-10-02 |
| SG190323A1 (en) | 2013-06-28 |
| WO2012076323A1 (en) | 2012-06-14 |
| US20130236424A1 (en) | 2013-09-12 |
| PH12013500952A1 (en) | 2013-07-08 |
| EP2465509A1 (en) | 2012-06-20 |
| AU2011340882B2 (en) | 2016-10-20 |
| RU2593321C2 (ru) | 2016-08-10 |
| AU2011340882A1 (en) | 2013-05-30 |
| MX2013005727A (es) | 2013-07-03 |
| US9763465B2 (en) | 2017-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013001433A1 (es) | Composicion que comprende al menos una n-acetil lactosamina, al menos un oligosacarido sialilado al menos un oligosacarido fucosilado; y su uso en la prevencion de infecciones respiratorias agudas y/o para aliviar los sintomas de dichas infecciones. | |
| CL2013001436A1 (es) | Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel. | |
| CL2013001470A1 (es) | Mezcla de oligosacaridos que comprende al menos una acetil-n-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado; producto alimenticio que comprende esta mezcla; y su uso para prevenir y reducir el riesgo y/o reducir la severidad y/o reducir la aparicion de alergias a alimentos y los efectos relacionados con la alergia a alimentos sobre la salud. | |
| CL2013003455A1 (es) | Uso de compuestos inhibidores de sglt-2 derivados de benceno, sustituidos por glucopiranosilo para prevenir, desacelerar la progresion, retrasar o tratar un trastorno metabolico en un pacientes con un agente neuroleptico; uso de la combinacion del inhibidor de sglt2 con un neuroleptico; y composicion farmaceutica de la combinacion. | |
| CL2013001472A1 (es) | Mezcla de oligosaridos que comprende 5-70% en peso de al menos un oligosacarido n-acetilado, 5-90% en peso de al menos un galacto-oligosacarido, 2-50% en peso de al menos un oligosacarido sialilado y 5-70% en peso de al menos un oligosacarido fucosilado; producto alimenticio que la comprende; y su uso para la prevencion y reduccion del riesgo y/o reduccion de la severidad y/o reduccion de la ocurrencia de alergias en alimentos. | |
| CL2013001471A1 (es) | Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado y un hidrolizado que comprende proteinas parcialmente y/o completamente hidrolizadas; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel. | |
| MX381599B (es) | Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria | |
| BR112012031616A2 (pt) | forma cristalina do inibidor de benzilbenzeno sglt2 | |
| CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
| CO6440531A2 (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
| CL2013001104A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras. | |
| CL2013000801A1 (es) | Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion | |
| IT1402907B1 (it) | Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose. | |
| BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
| CL2013001589A1 (es) | Uso de una emulsion que comprende 0,08% en peso o menos de aceite esencial antimicrobiano, goma acacia y agua para proporcionar un efecto antimicrobiano en una composicion acuosa; proceso para mejorar el efecto antimicrobiano de un aceite esencial antimicrobiano; y composicion acuosa que comprende una emulsion antimicrobiana. | |
| BR112013014189A2 (pt) | composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções | |
| BRPI0815821A2 (pt) | Composições e métodos que empregam antagonistas nmda para alcançar um efeito poupador de anestésico. | |
| CO7061069A2 (es) | Glucosaminoglucanos no anticogulantes que comprenden una unidad de repetición de disacárido y su uso médico | |
| CL2007002021A1 (es) | Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias. | |
| EA201290373A1 (ru) | Синергическая противовирусная композиция и ее применение | |
| CL2014000671A1 (es) | Composicion farmaceutica que comprende rifabutina, claritromicina y clofazimina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple y sus sintomas asociados, tiroiditis de hashimoto y sindrome de melkersson o sarcoidosis. | |
| BRPI0915527A2 (pt) | pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos | |
| CL2008000463A1 (es) | Compuestos derivados de benzofuranos sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar infecciones parasitarias. | |
| CL2008002758A1 (es) | Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento. | |
| BRPI0913839A2 (pt) | composição farmacêutica com glicosaminoglicanos e uso da mesma no tratamento de úlceras crônicas |